We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · August 22, 2020

Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in IBD

Inflammatory Bowel Diseases

 

Additional Info

Disclosure statements are available on the authors' profiles:

Inflammatory Bowel Diseases
Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases
Inflamm. Bowel Dis. 2020 Jul 17;26(8)1232-1238, EM Kim, C Randall, R Betancourt, S Keene, A Lilly, M Fowler, ES Dellon, HH Herfarth

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading